568 related articles for article (PubMed ID: 11507070)
1. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
[TBL] [Abstract][Full Text] [Related]
2. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
3. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
5. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
6. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100.
Wang XY; Chen X; Manjili MH; Repasky E; Henderson R; Subjeck JR
Cancer Res; 2003 May; 63(10):2553-60. PubMed ID: 12750279
[TBL] [Abstract][Full Text] [Related]
7. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
[TBL] [Abstract][Full Text] [Related]
8. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta.
Jia ZC; Zou LY; Ni B; Wan Y; Zhou W; Lv YB; Geng M; Wu YZ
Cancer Immunol Immunother; 2005 May; 54(5):446-52. PubMed ID: 15750831
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Prins RM; Odesa SK; Liau LM
Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
[TBL] [Abstract][Full Text] [Related]
10. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
11. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
[TBL] [Abstract][Full Text] [Related]
12. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity.
Hawkins WG; Gold JS; Dyall R; Wolchok JD; Hoos A; Bowne WB; Srinivasan R; Houghton AN; Lewis JJ
Surgery; 2000 Aug; 128(2):273-80. PubMed ID: 10923004
[TBL] [Abstract][Full Text] [Related]
13. The treatment and prevention of mouse melanoma with an oral DNA vaccine carried by attenuated Salmonella typhimurium.
Zhu X; Cai J; Huang J; Jiang X; Ren D
J Immunother; 2010 Jun; 33(5):453-60. PubMed ID: 20463603
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein.
Zhang M; Ishii K; Hisaeda H; Murata S; Chiba T; Tanaka K; Li Y; Obata C; Furue M; Himeno K
Immunology; 2004 Aug; 112(4):567-74. PubMed ID: 15270727
[TBL] [Abstract][Full Text] [Related]
15. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
16. An autologous oral DNA vaccine protects against murine melanoma.
Xiang R; Lode HN; Chao TH; Ruehlmann JM; Dolman CS; Rodriguez F; Whitton JL; Overwijk WW; Restifo NP; Reisfeld RA
Proc Natl Acad Sci U S A; 2000 May; 97(10):5492-7. PubMed ID: 10779556
[TBL] [Abstract][Full Text] [Related]
17. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
18. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
[TBL] [Abstract][Full Text] [Related]
19. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.
Zatloukal K; Schneeberger A; Berger M; Schmidt W; Koszik F; Kutil R; Cotten M; Wagner E; Buschle M; Maass G
J Immunol; 1995 Apr; 154(7):3406-19. PubMed ID: 7897222
[TBL] [Abstract][Full Text] [Related]
20. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
